Evaluation of GSK3862995B in Healthy Subjects and Patients with Chronic Obstructive Pulmonary Disease

The primary objective of this study is to evaluate the safety and tolerability of **GSK3862995B** in healthy participants and those with **Chronic Obstructive Pulmonary Disease (COPD)**. This is clinically relevant as it aims to determine the potential adverse effects and overall safety profile of the investigational product, which is crucial for assessing its suitability for further clinical development and potential therapeutic use in managing COPD.

The clinical trial involves a total of **55 participants** diagnosed with **Chronic Obstructive Pulmonary Disease**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants were selected to ensure a representative sample of the general population affected by this condition, without targeting any vulnerable groups. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The selection process was designed to include a diverse group of individuals, reflecting the typical demographic affected by the disease. The sponsor has not provided specific details regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the safety and efficacy of **GSK3862995B** in both healthy participants and those diagnosed with **Chronic Obstructive Pulmonary Disease (COPD)**. This study is structured as a **Phase 1** trial, which is typically focused on assessing the safety profile of the investigational product. The trial will employ a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial is from December 16, 2024, to January 2, 2026, encompassing both the recruitment and follow-up periods.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria will be assessed. This visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful screening, participants will be randomized into different study arms. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health status, collect data on the investigational product's effects, and ensure adherence to the study protocol. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the investigational product's impact.

The expected length of participant involvement will vary depending on the specific requirements of the study protocol, but it will generally align with the overall trial duration. Conditions that may lead to early termination from the study include adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial is designed to maintain the highest ethical standards, ensuring participant safety and data integrity throughout the study period.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Consequently, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included. The absence of this data precludes a comprehensive description of the treatments used in the study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on December 16, 2024, with an estimated completion date of January 2, 2026. Although specific efficacy endpoints and methods for measurement and analysis are not detailed, Phase 1 trials often utilize a combination of laboratory tests, imaging studies, and **biomarker** assessments to gather initial efficacy data. The trial will adhere to a predefined schedule for data collection and analysis, ensuring that all relevant efficacy parameters are systematically evaluated throughout the study duration.